Familial dilated cardiomyopathy (FDC) can involve more than an enlarged heart and reduced pumping function. In some families, disease is accompanied by abnormalities in the heart’s electrical conduction system, including atrioventricular block and sick sinus syndrome. A family-based genetic study examined this combination using next-generation sequencing and follow-up testing, identifying an LMNA variant that the authors considered a likely contributor to disease in the family studied.
The findings illustrate the value—and the limits—of genetic analysis in inherited cardiomyopathy. Detecting a rare variant can help explain a family pattern, but its significance depends on how it tracks with clinical findings and on supporting evidence. In this case, variants in three genes were identified, yet the evidence linking them to the family’s cardiomyopathy was not equally strong.
Familial dilated cardiomyopathy and inherited risk
Dilated cardiomyopathy (DCM) is characterized by enlargement of the heart’s chambers and impaired contractile function. When at least two closely related people meet diagnostic criteria for DCM, the condition may be classified as familial. Inherited variants are one possible cause, and the disease can have a complex genetic background rather than a single, straightforward explanation.
Many genes associated with DCM encode proteins involved in the heart muscle’s structure, contraction, or electrical activity. LMNA, which encodes lamins A and C, is of particular interest because these proteins help support the cell nucleus. Changes in LMNA have been associated with cardiomyopathy and disorders of cardiac conduction. As a result, clinicians evaluating a family with DCM may need to consider both structural heart disease and electrical abnormalities.
How the family study assessed genetic variants
The researchers investigated a family with a history of cardiomyopathy using pedigree analysis and genetic testing. They screened the coding regions and nearby splice sites of 325 genes associated with inherited diseases, including 61 genes associated with cardiac disease. The analysis used targeted exon capture and next-generation semiconductor sequencing. Candidate variants with a global minor allele frequency below 1% were then assessed, with Sanger sequencing used to verify selected findings in family members.
The proband was a 54-year-old woman with symptoms including chest discomfort and shortness of breath. Cardiac assessments showed left ventricular enlargement and a reduced left ventricular ejection fraction of 35%, alongside rhythm and conduction abnormalities. Other family members had a history of DCM, heart failure, or conduction problems. Three patients in the second generation underwent permanent pacemaker implantation in the context of sick sinus syndrome, atrioventricular block, or unstable cardiac electrophysiology.
LMNA p.E82K was the strongest candidate
Testing identified three rare missense variants: p.E82K in LMNA, p.F182L in KCNQ4, and p.G426S in EYA1. A missense variant changes the amino acid sequence of a protein. The authors focused on LMNA p.E82K as the variant most likely to contribute to FDC in this family.
Several observations supported that interpretation. The variant was present in multiple relatives, including family members with clinical findings, and the affected amino acid was conserved across the species examined, with the exception of the rat. The study also reported computational predictions suggesting a damaging effect on protein function. These findings are consistent with a possible role for LMNA p.E82K, but they do not establish a complete mechanism for how the variant leads to disease.
The study’s authors proposed that LMNA p.E82K may be associated with both DCM and conduction abnormalities. This is relevant because the family’s clinical picture included cardiac rhythm and conduction problems as well as impaired ventricular function. The study also discussed previous experimental work suggesting that the variant may affect connexin 43, a protein involved in communication between cardiac cells. That proposed connection offers one possible avenue for understanding the electrical findings, but the mechanism remains unresolved.
Why the other variants require separate interpretation
The KCNQ4 and EYA1 variants had previously been associated with conditions outside the family’s primary cardiac presentation. KCNQ4 p.F182L has been reported in connection with deafness, while EYA1 p.G426S has been associated with branchiootorenal or branchiootic syndrome. The family did not show those syndromes. One relative carrying the KCNQ4 variant had slight hearing impairment in the left ear, but the researchers found no broader pattern of hearing loss or the characteristic findings associated with the EYA1-related conditions.
This contrast is an important lesson in genetic interpretation: a variant’s presence in a person with disease does not, by itself, show that it caused that disease. Researchers also consider whether the variant follows the disease pattern within the family, whether the clinical features match known associations, and whether other evidence supports a causal role. In this report, the authors judged the two variants less likely to explain the family’s DCM than the LMNA finding.
Implications for family screening
The study supports a careful, family-centered approach to suspected inherited cardiomyopathy. A useful assessment may bring together:
- Pedigree information about cardiomyopathy, heart failure, and conduction disease among relatives.
- Clinical evaluation of cardiac structure, pumping function, and electrical activity.
- Genetic testing to identify candidate variants in relevant disease-associated genes.
- Variant interpretation that considers family segregation, clinical features, conservation, and other available evidence.
The report also highlights a limitation: DNA samples were unavailable for several relatives who had died from heart disease or heart failure. That made it harder to assess how consistently the LMNA variant tracked with disease across the family. In addition, findings from one family cannot establish how often the variant causes disease in other populations or determine an individual carrier’s future clinical course.
Conclusion
In the family studied, LMNA p.E82K was the leading genetic candidate for familial dilated cardiomyopathy accompanied by conduction abnormalities. The report shows how sequencing, pedigree analysis, and clinical assessment can be combined to investigate inherited disease, while underscoring that rare variants need careful interpretation. For families with a history of cardiomyopathy, genetic findings are most informative when evaluated alongside cardiac features and patterns across relatives—not in isolation.